Barclays PLC Aptevo Therapeutics Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$3.26 - $6.3 $39,772 - $76,860
12,200 Added 18.26%
79,001 $283,000
Q1 2022

May 16, 2022
BUY
$4.48 - $8.42 $299,268 - $562,464
66,801 New
66,801 $392,000

About Aptevo Therapeutics Inc.

APVO Quotes by TradingView
  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $24.5M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email